FDA Brief

Warning letters Drugs

FDA warning letter to

Center for Instrumental Analysis of China Pharmaceutical University

High riskIssued Jan 23, 2025Posted Feb 4, 2025Center for Drug Evaluation and Research (CDER)

Center for Instrumental Analysis of China Pharmaceutical University cited for incomplete API testing records and no quality unit.

What happened

FDA inspected the contract testing laboratory from September 18 to 20, 2024, in Nanjing, Jiangsu. Investigators found incomplete 1H NMR laboratory control records, archived testing data not provided during the inspection, shared login IDs with full administrative access on NMR computers, and no quality unit to ensure drugs were appropriately tested and results reported. The firm's September 23, 2024 response was inadequate, and the firm committed to cease all drug testing for the U.S. market.

What FDA found

  1. The laboratory's records for 1H NMR testing of API and intermediate samples were incomplete and did not document sample preparation, test procedures, system suitability, or second-person review.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  2. The firm stored older 1H NMR testing data on external hard drives and did not provide requested CGMP data for review during the inspection because it said retrieval would be difficult.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  3. The computerized NMR systems lacked adequate controls to prevent unauthorized access or changes, and multiple users shared one login ID with full administrative access.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  4. The firm did not establish a quality unit with defined responsibilities and procedures to ensure drugs were appropriately tested and results reported.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)

What FDA wants

FDA asks the firm to respond in writing within 15 working days with corrective actions and the requested assessments and plans, including documentation-system remediation, risk assessments for documentation and access controls, quality-unit remediation, and change-management assessment. FDA also asks the firm to clarify whether and when it intends to resume U.S. drug testing and to notify FDA before resuming CGMP operations.

Who should pay attention

  • drug manufacturers that use contract testing laboratories
  • API suppliers whose samples were tested by this lab
  • quality teams that rely on third-party laboratory data for CGMP decisions

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk